![](https://images.squarespace-cdn.com/content/v1/54c68ac6e4b06d2e36a4b8c9/1585411667181-4DAUOCOD82BM712P2DRA/image-asset.jpeg)
LATEST NEWS IN PROSTATE CANCER
Radium-223 (Alpharadin) A Novel Targeted Alpha-Emitter for Bone-Metastatic Castrate-Resistant Prostate Cancer
Radium-223 (or Alpharadin) is a new targeted alpha-emitting agent which has shown a prolongation of survival in castrate-resistant prostate cancer patients with bone-metastatic disease (5).